The case for pathogen-specific therapy.

Area of Science:

• Microbiology and Infectious Diseases
• Immunology
• Public Health

Background:

• Antimicrobial drug resistance and emerging pathogens complicate modern disease treatment.
• The shift to broad-spectrum antimicrobial therapy neglected diagnostics, fostering therapeutic empiricism.
• Widespread use of broad-spectrum antimicrobials has been linked to resistance and chronic diseases.

Discussion:

• Nonspecific antimicrobial therapy disrupts the human microflora, impacting the host-symbiont relationship.
• The long-term consequences of broad-spectrum antimicrobial use include fungal superinfections and antibiotic-associated colitis.
• Current strategies of nonspecific therapy are fundamentally unsound due to microflora damage.

Key Insights:

• Drug resistance and new pathogens challenge current microbial disease treatments.
• Broad-spectrum antimicrobials contribute to resistance and may play a role in chronic diseases like asthma.
• Damage to the human microbiome by nonspecific therapy has significant health implications.

Outlook:

• Development of immunotherapy and pathogen-specific therapies is crucial for future treatment strategies.
• Focusing on pathogen-specific approaches can mitigate the negative impacts of broad-spectrum antimicrobials.
• Research into novel therapeutic routes is needed to address the limitations of current antimicrobial chemotherapy.